These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37745119)

  • 21. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
    Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
    JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
    Berg DD; Docherty KF; Sattar N; Jarolim P; Welsh P; Jhund PS; Anand IS; Chopra V; de Boer RA; Kosiborod MN; Nicolau JC; O'Meara E; Schou M; Hammarstedt A; Langkilde AM; Lindholm D; Sjöstrand M; McMurray JJV; Sabatine MS; Morrow DA
    Circulation; 2022 Jan; 145(3):158-169. PubMed ID: 34743554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast growth factor 23 and Klotho as cardiovascular risk factors in heart transplant recipients.
    Przybylowski P; Wasilewski G; Janik L; Kozlowska S; Nowak E; Malyszko J
    Transplant Proc; 2014 Oct; 46(8):2848-51. PubMed ID: 25380933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
    Jiang J; Gao J; Zhang X; Li Y; Dang H; Liu Y; Chen W
    Front Cardiovasc Med; 2023; 10():1097066. PubMed ID: 37034349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
    Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
    JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry.
    Vaduganathan M; Greene SJ; Zhang S; Grau-Sepulveda M; DeVore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
    JAMA Cardiol; 2021 Mar; 6(3):267-275. PubMed ID: 33185662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left atrial function and maximal exercise capacity in heart failure with preserved and mid-range ejection fraction.
    Maffeis C; Morris DA; Belyavskiy E; Kropf M; Radhakrishnan AK; Zach V; Rozados da Conceicao C; Trippel TD; Pieske-Kraigher E; Rossi A; Pieske B; Edelmann F
    ESC Heart Fail; 2021 Feb; 8(1):116-128. PubMed ID: 33295106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
    Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
    Mc Causland FR; Claggett BL; Vaduganathan M; Desai AS; Jhund P; de Boer RA; Docherty K; Fang J; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
    JAMA Cardiol; 2023 Jan; 8(1):56-65. PubMed ID: 36326604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High serum fibroblast growth factor 21 levels were related to the prognosis and ventricular remodeling of heart failure patients with mildly reduced and reduced ejection fraction.
    Fan L; Gu L; Yao Y; Ma G
    Perfusion; 2024 Mar; 39(2):285-293. PubMed ID: 36321746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
    JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER.
    Desai AS; Jhund PS; Claggett BL; Vaduganathan M; Miao ZM; Kondo T; Barkoudah E; Brahimi A; Connolly E; Finn P; Lang NN; Mc Causland FR; McGrath M; Petrie MC; McMurray JJV; Solomon SD
    JAMA Cardiol; 2022 Dec; 7(12):1227-1234. PubMed ID: 36189985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.
    Adamson C; Welsh P; Docherty KF; de Boer RA; Diez M; Drożdż J; Dukát A; Inzucchi SE; Køber L; Kosiborod MN; Ljungman CEA; Martinez FA; Ponikowski P; Sabatine MS; Morrow DA; Lindholm D; Hammarstedt A; Boulton DW; Greasley PJ; Langkilde AM; Solomon SD; Sattar N; McMurray JJV; Jhund PS
    JACC Heart Fail; 2023 Mar; 11(3):291-304. PubMed ID: 36592046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Borlaug BA; Reddy YNV; Braun A; Sorimachi H; Omar M; Popovic D; Alogna A; Jensen MD; Carter R
    Circulation; 2023 Sep; 148(10):834-844. PubMed ID: 37534453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
    Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.